Given the unabated rise of specialty pharmaceuticals, issues related to cost and access are set to dominate health policy discussions for the foreseeable future as stakeholders – including pharmas, payers, prescribers and patients, as well as healthy but insured consumers – wrestle with ways to support innovation without breaking the bank. The most recent edition of Health Affairs, which was published online on October 6, contains a handful of papers authored by academic and industry researchers offering different perspectives, including a report from researchers at Duke University who analysed the real-world impact expensive specialty drugs are having on insurance premiums, while also offering new theories on best practices for cost-sharing methods. Read more here. (Source: FirstWord Pharma).
You are here: / / How Has The Rise Of Specialty Pharmaceuticals Impacted Consumers?